Rational Integration of Genomic Healthcare Technology: Evidence from PREDICT

A widely-held vision arising from the sequencing of the human genome is to guide health care decision-making with genetic data to improve patient care -a promise that is fueled by extraordinary advances in the discovery of genomic variation that predicts therapeutic response. Already, the Food and Drug Administration (FDA) recognizes many interactions between gene variants and drug outcomes; currently more than 70 drug labels include references to germline pharmacogenomic information that can affect prescribing across a wide array of diseases and conditions. Yet while scientific evidence underlying pharmacogenomics is expanding rapidly, parallel efforts to understand the economic incentives and behavioral changes related to characterizing individuals’ genetic risks are lacking.